Study

RNA Editing in breast cancer

Study ID Alternative Stable ID Type
EGAS00001000495 Transcriptome Analysis

Study Description

High-throughput sequencing screens suggest that RNA editing, which consists in the substitution of adenosine with inosine by the RNA-specific adenosine deaminase (ADAR) enzyme, occurs at several thousand positions across the human genome. Recent evidences have shown that RNA-editing could promote proliferation and carcinogenesis; however, the general principles of ADAR activity on the transcriptome and how ADAR is controlled in cancers remain to be established. The main aim of this project was to investigate the phenomenon of RNA editing in breast and other cancers. The frequency of A-to-I editing was evaluated in 58 breast cancers equally distributed among the different molecular subtypes and 10 normal breast tissues. The analysis was focused on defining: the relationship between the global amount of editing and ADAR expression; the ability to predict the level of editability of specific sites; the distribution of editing in normal and tumour samples and among different breast cancer subtypes; and the clinical, pathological and genomic factors affecting editing.

Study Datasets 4 datasets.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001000626
Exome sequencing data for tumor and matched normal samples of the EGAS00001000495 project.
Illumina HiSeq 2000 114
EGAD00001000627
Transcriptome sequencing data of tumor and 10 matched normal samples of the EGAS00001000495 project
Illumina HiSeq 2000 68
EGAD00001000708
AZIN1 amplicon sequencing data of the EGAS00001000495 project.
454 GS FLX Titanium 69
EGAD00010000847
Genotyping using Affymetrix SNP6.0
49

Who archives the data?

Publications

Citations

Retrieving...
Retrieving...
Retrieving...
Retrieving...
Retrieving...
Retrieving...